Prediction of efficacy for conversion from adjunctive therapy to monotherapy with eslicarbazepine acetate 800 mg once daily for partial-onset epilepsy
Soujanya Sunkaraneni,1 Julie A Passarell,2 Elizabeth A Ludwig,2 Jill Fiedler-Kelly,2 Janet K Pitner,1 Todd A Grinnell,1 David Blum1 1Sunovion Pharmaceuticals Inc., Marlborough, MA, USA; 2Cognigen Corporation (a SimulationsPlus company), Buffalo, NY, USA Purpose: Eslicarbazepine acetate (ESL) is a on...
Enregistré dans:
| Auteurs principaux: | , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Dove Medical Press
2017
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/cc916b7b6de44a4b81813f80ae1e3b03 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|